Pregnancy status was reported in 497 patients, with 74.0% being pregnant at least once during the trial. A multivariate Cox model was created to determine the HR for breast cancer events associated with pregnancy, which was 0.53 (95% CI, 0.27-1.04). Successful pregnancies were ob...
参考文献: [1].Partridge A, Niman SM, Ruggeri M, et al. Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer: Primary Results from the POSITIVE Trial (IBCSG 48-14 / BIG 8-13).2022 SABCS....
Breast cancer Young women Premenopausal women Pregnancy desire Endocrine therapy Treatment interruption 1. Introduction Young patients with hormone receptor positive (HR+) breast cancer (BC), receiving modern adjuvant endocrine therapy (ET) have excellent long-term outcomes [[1], [2], [3]]. Fertili...
Pregnancy is not a reason to delay treatment but oncologists should be vigilant for potential treatment-related complications to both the fetus and mother. Herein, we report a 29 year old female with metastatic hormone and Her-2 receptor positive inflammatory breast cancer who was found to have ...
Trastuzumab deruxtecan is an antibody–drug conjugate with high extracranial activity in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. We conducted the prospective, open-label, single-arm, phase 2 TUXEDO-1 trial. We enrolled patients aged ≥18 years with HER2...
Our study also proved that breast cancer patients with positive p53 expression detected by IHC were more likely to achieve tpCR (P = 0.032) and bpCR (P = 0.045) than those with negative p53 expression. However, in the EORTC 10994/BIG 1–00 trial, the presence of p53 mutations...
See how OPDIVO® (nivolumab) + YERVOY® (ipilimumab) performed in a clinical trial as first-line treatment for adults with advanced non-small cell lung cancer that tested positive for PD-L1 . Please see Indication and Important Safety Information.
See how OPDIVO® (nivolumab) + YERVOY® (ipilimumab) performed in a clinical trial as first-line treatment for adults with advanced non-small cell lung cancer that tested positive for PD-L1 . Please see Indication and Important Safety Information.
Hence, it is worth investigating the role of SRT in the setting of oligoprogressive breast cancer. Method AVATAR is a multicentre phase II registry trial of SRT with endocrine therapy and CDK 4/6 inhibitor for the management of advanced ER-positive HER2-negative breast cancer. The study aims ...
Fertility preservation and pregnancy in women with and without BRCA mutation-positive breast cancer. Oncologist. 2012; 17 :1409–1417.Rodriguez-Wallberg, K. A. & Oktay, K. Fertility preservation and pregnancy in women with and without BRCA mutation-positive breast cancer. The oncologist 17, 1409...